Fortress Biotech (FBIO) Competitors

Fortress Biotech (NASDAQ:FBIO) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.

Is FBIO or CDXS more profitable?

Fortress Biotech has a net margin of -84.53% compared to Codexis' net margin of -96.35%. Fortress Biotech's return on equity of 0.00% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	-84.53%	N/A	-34.93%
Codexis	-96.35%	-71.56%	-38.00%

Which has more volatility and risk, FBIO or CDXS?

Fortress Biotech has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Codexis has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500.

Do institutionals and insiders believe in FBIO or CDXS?

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 33.4% of Fortress Biotech shares are held by company insiders. Comparatively, 2.1% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in FBIO or CDXS?

Codexis received 23 more outperform votes than Fortress Biotech when rated by MarketBeat users. However, 63.69% of users gave Fortress Biotech an outperform vote while only 61.47% of users gave Codexis an outperform vote.

Company	Underperform	Outperform
Fortress Biotech	Outperform Votes 328 63.69%	Underperform Votes 187 36.31%
Codexis	Outperform Votes 351 61.47%	Underperform Votes 220 38.53%

Which has preferable earnings and valuation, FBIO or CDXS?

Fortress Biotech has higher earnings, but lower revenue than Codexis. Codexis is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$57.68M	0.78	-$60.64M	-$2.78	-0.55
Codexis	$59.35M	3.14	-$76.24M	-$0.90	-2.50

Do analysts rate FBIO or CDXS?

Fortress Biotech presently has a consensus price target of $21.00, indicating a potential upside of 1,281.58%. Codexis has a consensus price target of $8.33, indicating a potential upside of 270.37%. Given Fortress Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Fortress Biotech is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Codexis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Does the media prefer FBIO or CDXS?

In the previous week, Codexis had 4 more articles in the media than Fortress Biotech. MarketBeat recorded 7 mentions for Codexis and 3 mentions for Fortress Biotech. Codexis' average media sentiment score of 0.80 beat Fortress Biotech's score of 0.11 indicating that Codexis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Codexis	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fortress Biotech beats Codexis on 11 of the 18 factors compared between the two stocks.